Cargando…

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells

Neoadjuvant chemoradiotherapy followed by radical surgery is the standard treatment for patients with locally advanced low rectal cancer. However, several studies have reported that ionizing radiation (IR) activates nuclear factor kappa B (NF-κB) that causes radioresistance and induces matrix metall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugano, Hiroshi, Shirai, Yoshihiro, Horiuchi, Takashi, Saito, Nobuhiro, Shimada, Yohta, Eto, Ken, Uwagawa, Tadashi, Ohashi, Toya, Yanaga, Katsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210678/ https://www.ncbi.nlm.nih.gov/pubmed/30336548 http://dx.doi.org/10.3390/cancers10100386

Ejemplares similares

Correction: Hiroshi Sugano et al. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers 2018, 10, 386
por: Sugano, Hiroshi, et al.
Publicado: (2019)

Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells
por: Takada, Naoki, et al.
Publicado: (2021)

Glycogen synthase kinase‐3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells
por: Haruki, Koichiro, et al.
Publicado: (2017)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo
por: Saito, Nobuhiro, et al.
Publicado: (2018)

Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB
por: Shirai, Yoshihiro, et al.
Publicado: (2018)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Suppression of lysosomal acid alpha‐glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer
por: Hamura, Ryoga, et al.
Publicado: (2021)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
por: Kim, Joo Seong, et al.
Publicado: (2022)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
por: Han, Sung Joon, et al.
Publicado: (2018)

Nafamostat Mesilate: Can It Be Used as a Conduit Preserving Agent in Coronary Artery Bypass Surgery?
por: Yoon, Yoo Sang, et al.
Publicado: (2013)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway
por: Choi, Sujeong, et al.
Publicado: (2016)

Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells
por: Taniai, Tomohiko, et al.
Publicado: (2021)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations
por: Chen, Xuanmao, et al.
Publicado: (2010)

Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study
por: Lee, Yong Kyu, et al.
Publicado: (2014)

Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition
por: Chen, Tao, et al.
Publicado: (2014)

Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production
por: Kang, Min-Woong, et al.
Publicado: (2015)

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial
por: Choi, Ji-Young, et al.
Publicado: (2015)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
por: Lin, Yao, et al.
Publicado: (2022)

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials
por: Xie, Yu, et al.
Publicado: (2023)

Use of argatroban in combination with nafamostat mesilate in open-heart surgery for a pediatric patient with heparin-induced thrombocytopenia type II: a case report
por: Kawamoto, Shuji, et al.
Publicado: (2020)

Radical resection of a primary unresectable duodenal cancer after chemotherapy using S-1 and cisplatin: report of a case
por: Kanehira, Masaru, et al.
Publicado: (2017)

Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case
por: Tsunematsu, Masashi, et al.
Publicado: (2019)

Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient
por: Sato, Yohei, et al.
Publicado: (2015)

Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial
por: Hirota, Morihisa, et al.
Publicado: (2019)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle
por: Sato, Yohei, et al.
Publicado: (2016)

Metabolomic Profiling of Pompe Disease‐Induced Pluripotent Stem Cell‐Derived Cardiomyocytes Reveals That Oxidative Stress Is Associated with Cardiac and Skeletal Muscle Pathology
por: Sato, Yohei, et al.
Publicado: (2016)

Dual‐specificity tyrosine‐regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer
por: Ito, Daisuke, et al.
Publicado: (2017)

Crystal structure of nafamostat dimesylate
por: Fujii, Isao
Publicado: (2021)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Thrombomodulin expression impacts the recurrence and long‐term survival in pancreatic cancer
por: Sugano, Hiroshi, et al.
Publicado: (2021)

Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer
por: OGAWA, MASAICHI, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ub6vs7ko0pccgd7vsjmedjpkl0